CSL Limited
CSL Limited (CSLLY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cslly · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CSL Limited (CSLLY) measures how much investors pay for each dollar of the company's trailing earnings. CSLLY's current PE ratio of 23.56x is calculated by dividing its stock price of $17.12 by its TTM earnings per share of $2.98. −69.7% discount vs 5Y avg 77.7x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%65.6x
MedianQ3 · 75%285.9x
Max
At 23.56x, CSLLY's current P/E is lower than in 0% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CSL LimitedYou CSLLY | $66.3B | 23.56x | -95.3% | $2.98 |
 argenx SE ARGNF | $54.8B | 39.66x | -92.1% | $21.94 |
 Chugai Pharmaceutical Co., Ltd. CHGCF | $77.2B | 32.63x | -93.5% | $263.96 |
 Chugai Pharmaceutical Co., Ltd. CHGCY | $76.0B | 29.80x | -94.1% | $138.26 |
 GSK plc GLAXF | $94.4B | 12.94x | -97.4% | $1.41 |
 Genmab A/S GNMSF | $15.3B | 19.58x | -96.1% | $16.04 |
 Menicon Co Ltd MECNY | $26.9B | 2872.60x | +473.1% | $4.63 |
Industry Average 6 peers with valid PE | — | 501.20x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | 51.08x | $0.78 | -28.4% | |
2024-06-30 FY2024 | 71.36x | $0.68 | -12.0% | |
2023-06-30 FY2023 | 81.10x | $0.57 | +6.0% | |
2022-06-30 FY2022 | 76.51x | $0.60 | -29.5% | |
2021-06-30 FY2021 | 108.53x | $0.49 | -12.8% | |
2020-06-30 FY2020 | 124.40x | $0.40 | +73.9% | |
2019-06-30 FY2019 | 71.56x | $0.53 | -29.7% | |
2018-06-30 FY2018 | 101.74x | $0.35 | +7.3% | |
2017-06-30 FY2017 | 94.79x | $0.28 | +13.5% | |
2016-06-30 FY2016 | 83.50x | $0.25 | +39.3% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CSL Limited (CSLLY) measures how much investors pay for each dollar of the company's trailing earnings. CSLLY's current PE ratio of 23.56x is calculated by dividing its stock price of $17.12 by its TTM earnings per share of $2.98.
Frequently asked questions
CSLLY pe ratio · 6 questionsCSLLY's current PE ratio is 23.56x as of 2026-06-09, based on a stock price of $17.12 and TTM EPS of $2.98. Data sourced from Financial Modeling Prep via CSLLY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CSL Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09